Hyogo, Japan

Yoshihara Ikeda

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharmaceuticals Company Limited. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshihara Ikeda. Retrieved from https://idiyas.com/inventor/yoshihara-ikeda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yoshihara Ikeda

Introduction

Yoshihara Ikeda is a notable inventor based in Hyogo-ken, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on chemical compounds.

Latest Patents

Ikeda holds a patent for a 2,3-diaminopropionic acid derivative. This invention showcases his expertise in developing new chemical entities that can have various applications in medicine.

Career Highlights

Ikeda is associated with Sumitomo Pharmaceuticals Company Limited, where he has been instrumental in advancing research and development initiatives. His work has contributed to the company's reputation as a leader in the pharmaceutical industry.

Collaborations

Ikeda has collaborated with esteemed colleagues such as Yasuyuki Ueki and Hisakazu Kishimoto. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Yoshihara Ikeda's contributions to the field of pharmaceuticals through his patent and collaborations highlight his role as a significant inventor. His work continues to impact the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…